Crucell Strengthens its Vaccine Sales in the UK with a Dedicated Marketing and Sales Organization
Crucell N.V. announced the launch of its own dedicated marketing and sales organization in the United Kingdom by acquiring an experienced team, to further strengthen its vaccine sales position in one of the largest vaccine markets in Europe.
Crucell's UK team will market and sell Crucell's travel vaccines Epaxal® (aluminum-free hepatitis A vaccine), Vivotif® (oral typhoid fever vaccine) and Dukoral® (oral vaccine against cholera and travelers' diarrhea), as well as its registered virosomal adjuvanted influenza vaccine Inflexal® V. Distribution of the travel vaccines will start immediately and distribution of the influenza vaccines will start in 2010. Crucell has identified the UK as a high-potential market that deserves extra attention.
Previously, Crucell distributed its travel vaccines through the UK-based company MASTA Ltd, and influenza vaccines through Sanofi Pasteur MSD. With the establishment of its own dedicated sales team, Crucell will be able to focus on expanding market share for Crucell's travel and respiratory vaccines in the UK. This development is in line with Crucell's strategic focus on expanding sales in carefully selected markets.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
